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Purpose: To evaluate the prevalence of epilepsy in children (<16 yrs) with type 1 diabetes.
Methods: A review of clinical notes and investigations was carried out on all the children with type 1
diabetes who were under follow-up in the Paediatric Diabetes clinic at Alder Hey Children’s Hospital in
the year 2010.
Results: Of 285 children aged <16 years with type 1 diabetes, six also had epilepsy giving a prevalence of
21/1000. This is approximately six times greater than the prevalence of epilepsy in the general population
of children in UK.
Conclusion: Epilepsy appears to occur more frequently in children with type 1 diabetes than in the
general paediatric population.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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There are conﬂicting reports of a possible association between
type 1 diabetes mellitus (T1D) and epilepsy, particularly idiopathic
generalised epilepsy (IGE). Two studies,1,2 one exclusively
undertaken in adults,1 showed an increased prevalence of epilepsy
in patients withT1D; in contrast a single paediatric study
suggested that childhood epilepsy was no more frequently seen
in children with T1D than in the general paediatric population.3
Speculation on this possible association has focused on the role of
autoimmunity and speciﬁcally antibodies to glutamic acid
decarboxylase (GAD) which are elevated in many patients with
T1D4 and also in a number of neurological diseases.5 The aim of this
study was to try and conﬁrm or refute this reported association.
A review of clinical notes and investigations was carried out on
children with T1D who were under follow-up in the Paediatric
Diabetes Clinic at Alder Hey Children’s Hospital.
2. Patients and methods
Data were collected on all children aged <16 years who had a
diagnosis of T1D and who had attended the Paediatric Diabetes
Clinic at least once in the 12 months of 2010 prior to the study. The
clinic served a local (secondary) population. Data were extracted
from the patients’ case notes and the speciﬁc medical and nursing
notes. In addition, all the patients in the Diabetic Clinic database
were cross-checked with the EEG departmental database (which is* Corresponding author. Tel.: +44 7946438721.
E-mail address: renukaram@doctors.org.uk (R. Ramakrishnan).
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database held by the epilepsy nurse specialists at the hospital.
Finally, the paediatric neurologists and epilepsy nurse specialists
were also asked to identify all patients who were known to have
dual diagnoses of diabetes and epilepsy.
Epilepsy was diagnosed when two or more unprovoked
euglycemic (a laboratory-measured blood glucose of >3.9 mmol/
L) had been reliably documented. The diagnosis of epilepsy was
conﬁrmed following review of the medical case-notes and EEG by a
single paediatric neurologist (RA). All EEGs were recorded for a
minimum of 30 min in wakefulness. Neuroimaging (magnetic
resonance imaging [MRI] using a 1.5 T scanner) was also reviewed
to provide additional information on other potential causes for the
epilepsy. EEG and MRI were undertaken in our hospital.
Initially, all children reported to have experienced any ‘seizure’
were included in the study. Following review of all the
documentation, those children with conﬁrmed provoked and
speciﬁcally hypoglycaemic seizures and Children with a known
perinatal history of hypoxic-ischaemic encephalopathy, cerebro-
spinal ﬂuid-conﬁrmed diagnosis of meningitis or encephalitis or
late-onset post-traumatic epilepsy were excluded.
3. Results
Data were analysed for 285 children (156 males and 129
females) aged less than 16 years with T1D. Of these 285, six
children had a conﬁrmed diagnosis of epilepsy, ﬁve with a probable
IGE (Table 1).
Another child had experienced two seizures caused by
hypoglycaemia (on both occasions blood levels <2 mmol/L) and
was excluded. No child with diabetes had experienced any othervier Ltd. All rights reserved.
Table 1
Clinical, EEG and neuroimaging (MRI) ﬁndings of the six children with epilepsy.
Sex Age at diabetes
diagnosis (yrs)
Age at epilepsy
diagnosis (yrs)
Type of seizure AED Family history
of diabetes
Family history
of epilepsy
MRI (1.5 T) EEG (routine,
non-sleep deprived)
1. M 1.6 6 GTC VPA N Y (GTC) Normal Normal
2. F 14.9 14.6 GTC LEV Y N Normal Photosensitive
3. M 8.6 12 GTC None N N Not done Generalised sharp waves
4. M 2 7 Complex partial;
20 GTC (rare)
LTG N N Abnormal (PVL) Right occipital focal sharp waves
5. F 4.8 5.6 GTC VPA Y Y (GTC) Normal Normal
6. M 6.5 10 Absence VPA N N Not done Generalised spike and wave
at 3 Hz
GTC: generalised tonic-clonic; 20 GTC: secondary generalised tonic-clonic; VPA: sodium valproate; LEV: levetiracetam; LTG: lamotrigine; MRI: magnetic resonance imaging;
EEG: electroencephalograph; PVL: periventricular leucomalacia.
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of epilepsy. Neonatal seizures had not been documented in the
child With PVL (patient 4 in Table 1).
Diabetes preceded epilepsy in ﬁve of the six patients; in the
remaining patient (patient 2), diabetes was diagnosed a few
months after the diagnosis of epilepsy.
In one patient there was a family history of T1D but not
epilepsy; in another there was a family history of an IGE but not
diabetes. One patient had a family history of both and in three
there was no family history of diabetes or epilepsy.
All patients underwent a routine EEG and cerebral MRI was
performed in four. The EEG was abnormal in three (one each
showing generalised spike and wave activity, a grade 3 photo-
paroxysmal response and focal sharp and slow wave activity),
normal in two and equivocal (showing brief paroxysms of
generalised sharp wave activity) in one. MRI was normal in three
of the four in whom it was undertaken; one showed mild PVL (this
patient has a spastic diplegia; patient 4).
Five of the six patients received an anti-epileptic drug; the
family of the remaining patient (patient 3) declined treatment. Five
of the six patients have been seizure-free for between 6 and 18
months, including the patient not receiving an AED; patient 4
continues to experience brief focal seizures as manifest by periods
of unresponsiveness, head deviation and automatisms every 6
weeks.
This gives an epilepsy prevalence of 21 per 1000 (2.1%) in this
diabetic population. If only the ﬁve children with IGE are included,
the prevalence is 17.5 per 1000 children (1.75%). The reported
prevalence of epilepsy in a general paediatric population (<16
years) varies from approximately 3.6 (Joint Epilepsy Council
document published in 2005: www.jointepilepsycouncil.org.uk/
downloads/Epilepsy%20Prevalence%20Incidence%20an-
d%20Other%20Statistics.pdf [accessed August 2011]) to 5 per
1000.6 This suggests that in our population there may be between
over three and almost six-fold increase in epilepsy in children with
T1D.
4. Discussion
The issue whether individuals with T1D are at increased risk of
epilepsy because of a lowered threshold or increased susceptibil-
ity has been addressed in a very small number of studies1–3 and
with conﬂicting results. Our study, ascertained from a UK
paediatric diabetes clinic database, has shown over a three to
almost a six-fold increase in the prevalence of IGE in children with
T1D.
A UK study by McCorry et al. showed a four-fold increase in risk
of T1D in young adults with IGE.1 Their study, with patients
accessed from an epilepsy and not diabetes clinic population, also
showed that six of their seven patients with both conditions
developed diabetes prior to their epilepsy.1 Similar ﬁndings were
reported from an Italian diabetic clinic with 6 of 249 patients withT1D having epilepsy (four, IGE and two idiopathic focal epilepsy);
epilepsy had an onset <15 years of age in all six and prior to
diabetes in one patient.2 However, the ﬁndings of both studies are
in contrast to an Australian paediatric study which showed no
increased risk of IGE in their paediatric population with T1D.3 The
prevalence of active epilepsy in their diabetic population was 8.7
per 1000 compared to 5–10 per 1000 in their general population.
However, this latter ﬁgure is considerably higher than the cited
prevalence data of epilepsy for the general paediatric population in
the UK and this difference could in part explain their ﬁnding that
they found no association between T1D and epilepsy.
A number of hypotheses have been postulated to explain the
increased prevalence of epilepsy, and speciﬁcally IGE, in individu-
als with T1D. The focus seems to be an auto-immune mecha-
nism.5,7,8 It is not possible to comment on the postulated shared
auto-immune pathogenesis of both T1D and IGE in our study
because anti-GAD antibodies were not measured in any of our
diabetic population. In addition, there may be subtle antigenic
differences between epitopes recognised by anti-GAD antibodies
in patients with IGE and type 1 diabetes.8 However, it would seem
appropriate to consider the possibility of a genetic component, in
view of the likelihood that many of the IGEs are considered to have
a genetic basis.
There are clear imitations with this study, many of which have
been noted previously1–3 and which relate to the retrospective
nature of the study and accurate case-ascertainment of epilepsy.
These limitations could be addressed by a prospective and multi-
centre population study which includes techniques that max-
imises the accurate diagnosis of both hypoglycaemic and unpro-
voked (epileptic) seizures. Ideally, such a study should also use
more objective biochemical (such as anti-GAD antibodies using
highly speciﬁc assays) and genetic markers.
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